| Name | Title | Contact Details |
|---|---|---|
Collin Russell |
Director of Talent , Culture | Profile |
Collin Russell |
Vice President of People | Profile |
Extend Fertility is the first service in the U.S. focused exclusively on women who want to proactively preserve their fertility options.
Renovo Solutions is a Santa Ana, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ALZYN is a development stage company pursuing a unique approach to retard the progress of Alzheimer`s Disease. The science originated at the Florida State University`s College of Medicine.
Wellbiz Brands, Inc. is the nation`s premiere franchisor of wellness, fitness and beauty brands. With more than 600 locations, WellBiz Brands is uniquely qualified to serve the growing needs of the health and beauty conscious consumer through recurring revenue experience-based brands including Elements Massage®, Amazing Lash Studio® and Fitness Together®. Backed by a management team with nearly a century of combined leadership experience, WellBiz Brands accelerates scalable and predictable revenue growth by providing a robust platform of shared services, infrastructure and support. The company claimed three spots on the 2018 Inc. 5000 Fastest Growing Companies list and is headquartered in Englewood, Colorado.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.